Who are Lumify®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eye injection (Mydrane), Articaine Hydrochloride + Epinephrine, Entecavir+Carvedilol, Metoprolol succinate + doxazosin, Norepinephrine (10 µg boluses), Doxazosin extended release.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lumify.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Lumify® — Competitive Intelligence Brief

Lumify® (Lumify®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic receptor agonist. Area: Ophthalmology.

marketed Alpha-1 adrenergic receptor agonist Alpha-1 adrenergic receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Lumify® (Lumify®) — Bausch & Lomb Incorporated. Lumify is a selective alpha-1 adrenergic receptor agonist that constricts blood vessels in the eye to reduce redness.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lumify® TARGET	Lumify®	Bausch & Lomb Incorporated	marketed	Alpha-1 adrenergic receptor agonist	Alpha-1 adrenergic receptor
Eye injection (Mydrane)	Eye injection (Mydrane)	Medical University of Graz	marketed	Ophthalmic combination agent (mydriatic + anesthetic)	Muscarinic acetylcholine receptors (tropicamide); alpha-1 adrenergic receptors (phenylephrine); sodium channels (lidocaine)
Articaine Hydrochloride + Epinephrine	Articaine Hydrochloride + Epinephrine	Ankara Yildirim Beyazıt University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
Entecavir+Carvedilol	Entecavir+Carvedilol	ShuGuang Hospital	marketed	Antiviral + Beta-blocker combination	HBV reverse transcriptase; beta-1, beta-2, and alpha-1 adrenergic receptors
Metoprolol succinate + doxazosin	Metoprolol succinate + doxazosin	University of Colorado, Denver	marketed	Beta-blocker + Alpha-1 adrenergic antagonist combination	Beta-1 adrenergic receptor; Alpha-1 adrenergic receptor
Norepinephrine (10 µg boluses)	Norepinephrine (10 µg boluses)	Hopital Charles Nicolle	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; Beta-1 adrenergic receptor
Doxazosin extended release	Doxazosin extended release	University of Arkansas	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic receptor agonist class)

Bausch & Lomb Incorporated · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lumify® — Competitive Intelligence Brief. https://druglandscape.com/ci/lumify. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab